Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024
Aim. To evaluate the effect of the use of the double antiplatelet therapy (DAT) with ticagrelor compared to DAT with clopidogrel and antithrombotic therapy with acetyl salicylic acid (ASA) in patients with acute coronary syndrome and patients with high coronary risk on the target indicator (CP) of t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-01-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4819 |
| _version_ | 1797856619798724608 |
|---|---|
| author | M. V. Zhuravleva S. K. Zyryanov F. N. Paleev A. N. Yakovlev T. V. Marin Yu. V. Gagarina |
| author_facet | M. V. Zhuravleva S. K. Zyryanov F. N. Paleev A. N. Yakovlev T. V. Marin Yu. V. Gagarina |
| author_sort | M. V. Zhuravleva |
| collection | DOAJ |
| description | Aim. To evaluate the effect of the use of the double antiplatelet therapy (DAT) with ticagrelor compared to DAT with clopidogrel and antithrombotic therapy with acetyl salicylic acid (ASA) in patients with acute coronary syndrome and patients with high coronary risk on the target indicator (CP) of the state program (GP) “Development of Healthcare” and the federal project “Fight against cardiovascular diseases” — reducing mortality from diseases of the circulatory system (BSC).Material and methods. All adult Russian patients with a diagnosis of ACS eligible for DAT were considered as the target population; in the second and third years, only patients with high coronary risk continued treatment. The calculation of the number of deaths that can be prevented using DAT ticagrelor 90 mg + ASA vs DAT of clopidogrel + ASA within 1st year from the date of diagnosis was based on the clinical efficacy data of the PLATO study. The number of deaths that can be prevented with the use of DAT ticagrelor 60 mg + ASA — instead of ASA monotherapy patients with a history of myocardial infarction was made based in the clinical efficacy results of the PEGASUS study. It was calculated what proportion of the target indicators could be achieved in 2022-24 years by using DAT with ticagrelor instead of clopidogrel or ASA monotherapy.Results. The use of DAT with ticagrelor vs DAT with clopidogrel or ASA for the treatment of patients with ACS will prevent additional 5389, 5704 and 6012 deaths in 2022-2024, that will ensure the implementation of the CP “reduction of mortality from BSC” GP “Development of healthcare” in the Russian Federation by 36,9%, 26,0% and 20,6% respectively.Conclusion. The use of DAT with ticagrelor for the treatment of patients with acute coronary syndrome ensure the implementation of the CP “reduction of mortality from BSC” GP “Development of healthcare” in the Russian Federation in 2024 by 20,6%. |
| first_indexed | 2024-04-09T20:43:23Z |
| format | Article |
| id | doaj.art-72881da139644a0e83c2f42ee1216121 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:43:23Z |
| publishDate | 2022-01-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-72881da139644a0e83c2f42ee12161212023-03-29T21:23:40Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202022-01-01261210.15829/1560-4071-2021-48193456Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024M. V. Zhuravleva0S. K. Zyryanov1F. N. Paleev2A. N. Yakovlev3T. V. Marin4Yu. V. Gagarina5Scientific Center for Expert Evaluation of Medicinal Products; I.M. Sechenov First Moscow State Medical University (Sechenov University)Peoples’ Friendship University of RussiaNational Medical Research Center of CardiologyAlmazov National Medical Research CenterI.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)Aim. To evaluate the effect of the use of the double antiplatelet therapy (DAT) with ticagrelor compared to DAT with clopidogrel and antithrombotic therapy with acetyl salicylic acid (ASA) in patients with acute coronary syndrome and patients with high coronary risk on the target indicator (CP) of the state program (GP) “Development of Healthcare” and the federal project “Fight against cardiovascular diseases” — reducing mortality from diseases of the circulatory system (BSC).Material and methods. All adult Russian patients with a diagnosis of ACS eligible for DAT were considered as the target population; in the second and third years, only patients with high coronary risk continued treatment. The calculation of the number of deaths that can be prevented using DAT ticagrelor 90 mg + ASA vs DAT of clopidogrel + ASA within 1st year from the date of diagnosis was based on the clinical efficacy data of the PLATO study. The number of deaths that can be prevented with the use of DAT ticagrelor 60 mg + ASA — instead of ASA monotherapy patients with a history of myocardial infarction was made based in the clinical efficacy results of the PEGASUS study. It was calculated what proportion of the target indicators could be achieved in 2022-24 years by using DAT with ticagrelor instead of clopidogrel or ASA monotherapy.Results. The use of DAT with ticagrelor vs DAT with clopidogrel or ASA for the treatment of patients with ACS will prevent additional 5389, 5704 and 6012 deaths in 2022-2024, that will ensure the implementation of the CP “reduction of mortality from BSC” GP “Development of healthcare” in the Russian Federation by 36,9%, 26,0% and 20,6% respectively.Conclusion. The use of DAT with ticagrelor for the treatment of patients with acute coronary syndrome ensure the implementation of the CP “reduction of mortality from BSC” GP “Development of healthcare” in the Russian Federation in 2024 by 20,6%.https://russjcardiol.elpub.ru/jour/article/view/4819ticagrelorsecondary prevention of cardiovascular diseasestarget indicatorsmortality from circulatory system diseasesmortality from myocardial infarctionstate program “development of healthcare”federal project “fight against cardiovascular diseases” |
| spellingShingle | M. V. Zhuravleva S. K. Zyryanov F. N. Paleev A. N. Yakovlev T. V. Marin Yu. V. Gagarina Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024 Российский кардиологический журнал ticagrelor secondary prevention of cardiovascular diseases target indicators mortality from circulatory system diseases mortality from myocardial infarction state program “development of healthcare” federal project “fight against cardiovascular diseases” |
| title | Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024 |
| title_full | Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024 |
| title_fullStr | Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024 |
| title_full_unstemmed | Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024 |
| title_short | Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024 |
| title_sort | evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator reduction of mortality from diseases of the circulatory system in 2022 2024 |
| topic | ticagrelor secondary prevention of cardiovascular diseases target indicators mortality from circulatory system diseases mortality from myocardial infarction state program “development of healthcare” federal project “fight against cardiovascular diseases” |
| url | https://russjcardiol.elpub.ru/jour/article/view/4819 |
| work_keys_str_mv | AT mvzhuravleva evaluationoftheeffectoftheuseofthedrugticagrelorinpatientswithacutecoronarysyndromeonachievingthetargetindicatorreductionofmortalityfromdiseasesofthecirculatorysystemin20222024 AT skzyryanov evaluationoftheeffectoftheuseofthedrugticagrelorinpatientswithacutecoronarysyndromeonachievingthetargetindicatorreductionofmortalityfromdiseasesofthecirculatorysystemin20222024 AT fnpaleev evaluationoftheeffectoftheuseofthedrugticagrelorinpatientswithacutecoronarysyndromeonachievingthetargetindicatorreductionofmortalityfromdiseasesofthecirculatorysystemin20222024 AT anyakovlev evaluationoftheeffectoftheuseofthedrugticagrelorinpatientswithacutecoronarysyndromeonachievingthetargetindicatorreductionofmortalityfromdiseasesofthecirculatorysystemin20222024 AT tvmarin evaluationoftheeffectoftheuseofthedrugticagrelorinpatientswithacutecoronarysyndromeonachievingthetargetindicatorreductionofmortalityfromdiseasesofthecirculatorysystemin20222024 AT yuvgagarina evaluationoftheeffectoftheuseofthedrugticagrelorinpatientswithacutecoronarysyndromeonachievingthetargetindicatorreductionofmortalityfromdiseasesofthecirculatorysystemin20222024 |